Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study.

ABSTRACT:

Backgrounds

Little is known about whether prior chemoimmunotherapy (CTI) affects the efficacy of sequential treatment in patients with extensive-stage (ES) small-cell lung cancer (SCLC). Our preliminary study explored what kinds of biomarkers are associated with the outcomes of CTI followed by amrubicin (AMR) as a second-line treatment.

Methods

We retrospectively evaluated 45 patients with relapsed SCLC who underwent CTI followed by AMR monotherapy from December 2019 to December 2023. Clinical data and inflammatory and nutritional factors, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, systemic immune-inflammation index, prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and Glasgow prognostic score before init

SUBMITTER: Kaira K 

PROVIDER: S-EPMC12541839 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature